Gsk (GSK) Research & Development (2009 - 2026)

Gsk (GSK) has 18 years of Research & Development data on file, last reported at -$6.9 billion in Q3 2026.

• For the quarter ending Q3 2026, Research & Development changed N/A year-over-year to -$6.9 billion; the trailing twelve-month figure through Sep 2026 stood at -$23.9 billion (changed N/A YoY), and the FY2025 full-year result was -$10.0 billion, down 22.33% from the prior year.
• Research & Development was -$6.9 billion for Q3 2026 at Gsk, down from -$4.7 billion in the prior quarter.
• In the past five years, Research & Development ranged from a high of -$1.5 billion in Q1 2022 to a low of -$10.0 billion in Q4 2025.
• A 5-year average of -$3.6 billion and a median of -$2.0 billion in 2023 frame the typical range for Research & Development.
• The largest YoY upside for Research & Development was 18.74% in 2022 against a maximum downside of 114.42% in 2022.
• Gsk's Research & Development stood at -$6.4 billion in 2022, then fell by 19.99% to -$7.7 billion in 2023, then slipped by 6.37% to -$8.2 billion in 2024, then decreased by 21.83% to -$10.0 billion in 2025, then soared by 30.81% to -$6.9 billion in 2026.
• Per Business Quant data, the three most recent Research & Development figures were -$6.9 billion in Q3 2026, -$4.7 billion in Q2 2026, and -$2.3 billion in Q1 2026.